Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Helmerich & Payne Inc. Common Stock (HP) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance

Helmerich & Payne Inc. Common StockTrade
Revolution Medicines Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Helmerich & Payne Inc. Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.91B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 10.3× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays a 2.56% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and Revolution Medicines Inc. Common Stock for 2 Days on average.

HPRVMD
Market Cap
$3.91B$40.39B
Volume
800,3822,941,009
Sector
EnergyHealth
52-Week High
$47.64$221.15
52-Week Low
$23.11$49.56
Typical Hold Time
0 Days2 Days
Enterprise Value
$5.54B$37.09B
Dividend Yield
2.56%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Helmerich & Payne Inc. Common Stock

No Aura AI signal available yet.

Revolution Medicines Inc. Common Stock

Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.

The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HP
100% Buy0% Sell
Avg holding period · 0 Days
RVMD
51% Buy49% Sell
Avg holding period · 2 Days

About Helmerich & Payne Inc. Common Stock

Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.

Read more on HP →

About Revolution Medicines Inc. Common Stock

Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.

Read more on RVMD →